Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains
Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, announced today a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to optimize CAR designs for cellular therapy.